[go: up one dir, main page]

FR2783839B1 - Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire - Google Patents

Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire

Info

Publication number
FR2783839B1
FR2783839B1 FR9812000A FR9812000A FR2783839B1 FR 2783839 B1 FR2783839 B1 FR 2783839B1 FR 9812000 A FR9812000 A FR 9812000A FR 9812000 A FR9812000 A FR 9812000A FR 2783839 B1 FR2783839 B1 FR 2783839B1
Authority
FR
France
Prior art keywords
specific promoters
control tissue
tissue expression
hybrid specific
hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9812000A
Other languages
English (en)
Other versions
FR2783839A1 (fr
Inventor
Didier Branellec
Raphael Darteil
Abderrahim Mahfoudi
Daniel Scherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9812000A priority Critical patent/FR2783839B1/fr
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Priority to AU56324/99A priority patent/AU775717B2/en
Priority to JP2000572355A priority patent/JP2002525109A/ja
Priority to CN99811334A priority patent/CN1326506A/zh
Priority to CA002343922A priority patent/CA2343922A1/fr
Priority to PCT/FR1999/002265 priority patent/WO2000018908A1/fr
Priority to IL14210799A priority patent/IL142107A0/xx
Priority to EP99943036A priority patent/EP1115857A1/fr
Priority to KR1020017003768A priority patent/KR20010075338A/ko
Priority to HU0105230A priority patent/HUP0105230A3/hu
Publication of FR2783839A1 publication Critical patent/FR2783839A1/fr
Application granted granted Critical
Publication of FR2783839B1 publication Critical patent/FR2783839B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR9812000A 1998-09-25 1998-09-25 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire Expired - Fee Related FR2783839B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR9812000A FR2783839B1 (fr) 1998-09-25 1998-09-25 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
KR1020017003768A KR20010075338A (ko) 1998-09-25 1999-09-23 조직 발현을 제어하기 위한 특정 하이브리드 프로모터의용도
CN99811334A CN1326506A (zh) 1998-09-25 1999-09-23 特异性杂合启动子控制组织表达的应用
CA002343922A CA2343922A1 (fr) 1998-09-25 1999-09-23 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
PCT/FR1999/002265 WO2000018908A1 (fr) 1998-09-25 1999-09-23 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
IL14210799A IL142107A0 (en) 1998-09-25 1999-09-23 Use of specific hybrid promoters for controlling tissue expression
AU56324/99A AU775717B2 (en) 1998-09-25 1999-09-23 Use of specific hybrid promoters for controlling tissue expression
JP2000572355A JP2002525109A (ja) 1998-09-25 1999-09-23 組織発現を調節するための特異的ハイブリッドプロモーターの使用
HU0105230A HUP0105230A3 (en) 1998-09-25 1999-09-23 Use of specific hybrid promoters for controlling tissue expression
EP99943036A EP1115857A1 (fr) 1998-09-25 1999-09-23 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9812000A FR2783839B1 (fr) 1998-09-25 1998-09-25 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire

Publications (2)

Publication Number Publication Date
FR2783839A1 FR2783839A1 (fr) 2000-03-31
FR2783839B1 true FR2783839B1 (fr) 2002-12-06

Family

ID=9530839

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9812000A Expired - Fee Related FR2783839B1 (fr) 1998-09-25 1998-09-25 Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire

Country Status (1)

Country Link
FR (1) FR2783839B1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266490A (en) * 1991-03-28 1993-11-30 Regeneron Pharmaceuticals, Inc. Mammalian expression vector
US5298422A (en) * 1991-11-06 1994-03-29 Baylor College Of Medicine Myogenic vector systems
DK0787200T3 (da) * 1994-10-28 2005-08-15 Univ Pennsylvania Forbedret adenovirus og fremgangsmåder til anvendelse heraf
JP4131569B2 (ja) * 1996-12-02 2008-08-13 バレンティス・インコーポレーテッド インシュリン様成長因子ｉ（ｉｇｆ−ｉ）発現系及び使用法

Also Published As

Publication number Publication date
FR2783839A1 (fr) 2000-03-31

Similar Documents

Publication Publication Date Title
FR2798590B1 (fr) Utilisation de l'alverine pour diminuer les rides
DE69621536D1 (de) Absorbierende Wegwerfunterwäsche
EP1064391A4 (fr) Modulation antisens de l'expression du gene mdm2 humain
DE69635933D1 (de) Elektrochirurgische Entfernung von Geweben
ID22216A (id) Penggunaan antagonis-antagonis reseptor kanabinoid pusat untuk mengatur selera makan
DE69510836D1 (de) An den Körper anschmiegender absorbierender Artikel
FR2728457B1 (fr) Valve artificielle pour vaisseau sanguin
DE69812606D1 (de) Künstliche körperflüssigkeit
FR2764797B1 (fr) Forme pour incision corneenne multiplans
EP0861082A4 (fr) Traitement de l'insuffisance de la membrane tissulaire
FR2738573B1 (fr) Utilisation en tant qu'agents thermoepaississants de copolymeres multiblocs
FR2783839B1 (fr) Utilisation de promoteurs specifiques hybrides pour controler l'expression tissulaire
PT928197E (pt) Utilizacao de proteinas como agentes contra doencas de natureza autoimunitaria
NO993054D0 (no) Kasserbar absorberende gjenstand for lokalt vedheftende feste til en bµrers hud
FR2746015B1 (fr) Utilisation de l'octopirox comme agent depigmentant
HUP0105230A3 (en) Use of specific hybrid promoters for controlling tissue expression
DE69929672D1 (de) Steuereinheit für Funktionen zahnärtztlicher Handstücke
FR2773076B1 (fr) Utilisation de la flavine-adenine-dinucleotide pour la preparation de compositions ophtalmiques utiles pour le traitement de l'oeil sec
FR2749512B1 (fr) Utilisation de l'acetyl dl leucine pour le traitement des tremblements
FR2741802B1 (fr) Utilisation de melatonine pour traiter les peaux sensibles
FR2801787B1 (fr) Nouvelles compositions cosmetiques pour ameliorer l'elasticite des tissus de soutien
DE69609535D1 (de) Enthaarungswachsapplikator mit mehreren Freiheitsgraden
FR2744905B3 (fr) Attachement extracoronaire pour prothese dentaire
KR960009980U (ko) 여성용 생리대
FR2717174B1 (fr) Utilisation de pipéridinoéthyl esters de l'acide 4-amino-5-chloro-2-méthoxybenzoïque comme 5-HT4 agonistes.

Legal Events

Date Code Title Description
CD Change of name or company name
ST Notification of lapse

Effective date: 20060531